“The global market for Crispr gene-editing products as medicine, to develop new crops (such as spicy tomatoes or long-life mushrooms) and other uses is predicted to be $5.3bn by 2025. Continued advances in Crispr precision and ease of use, like the just reported prime editing approach, are likely to make that number even higher. Crispr gene editing has the potential to treat a myriad of monogenic diseases from sickle cell anaemia to muscular dystrophy and cancer. Parents may one day be able to genetically customise their children’s health, physical features and abilities. Crispr will be the genetic scissors that tailor the human gene pool.”
More on Gene editing like Crispr is too important to be left to scientists alone via The Guardian.